N
Nobuyuki Susumu
Researcher at International University of Health and Welfare
Publications - 162
Citations - 4121
Nobuyuki Susumu is an academic researcher from International University of Health and Welfare. The author has contributed to research in topics: Endometrial cancer & Cancer. The author has an hindex of 32, co-authored 159 publications receiving 3730 citations. Previous affiliations of Nobuyuki Susumu include Keio University.
Papers
More filters
Journal ArticleDOI
Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Nobuyuki Susumu,Satoru Sagae,Yasuhiro Udagawa,Kenji Niwa,Hiroyuki Kuramoto,Shinji Satoh,Ryuichi Kudo +6 more
TL;DR: Adjuvant chemotherapy may be a useful alternative to radiotherapy for intermediate-risk endometrial cancer patients and among 120 patients in a high- to intermediate- risk group, the CAP group had a significantly higher PFS rate and higher OS rate than the PRT group.
Journal ArticleDOI
miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer
Tomohiko Tsuruta,Ken Ichi Kozaki,Atsushi Uesugi,Mayuko Furuta,Akira Hirasawa,Issei Imoto,Nobuyuki Susumu,Daisuke Aoki,Johji Inazawa +8 more
TL;DR: A central role is defined for miR-152 in endometrial cancer, and its use in new therapeutic strategies to treat this cancer is suggested, as well as how its epigenetic silencing can driveendometrial carcinogenesis.
Journal Article
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Akira Hirasawa,Fumiko Saito-Ohara,Jun Inoue,Jun Inoue,Daisuke Aoki,Nobuyuki Susumu,Tetsuji Yokoyama,Shiro Nozawa,Johji Inazawa,Issei Imoto +9 more
TL;DR: Information gained from a relatively large panel of OCCA tumors suggested that 17q21-q24 gain and consequent overexpression of two potential targets, PPM1D and APPBP2, are associated with malignant phenotypes of this tumor and may be useful predictors for prognosis.
Journal ArticleDOI
Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study
Matthew A. Powell,Virginia L. Filiaci,Peter G. Rose,Robert S. Mannel,Parviz Hanjani,Koen DeGeest,Brigitte Miller,Nobuyuki Susumu,Frederick R. Ueland +8 more
TL;DR: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.
Journal ArticleDOI
Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation.
Shinichi Komiyama,Daisuke Aoki,Eiichiro Tominaga,Nobuyuki Susumu,Yasuhiro Udagawa,Shiro Nozawa +5 more
TL;DR: Patients having ovarian clear cell carcinoma with pelvic endometRIosis exhibited a better prognosis than those without endometriosis, especially those patients with stage I cancer.